Evaluation of Predictive Risk Factors of Chemotherapy-induced Nausea and Vomiting

Overview

The most common toxicity of chemotherapy is nausea and vomiting, and appropriate management of these toxicities can help patients improve tolerance for chemotherapy. Anti-emetics including dopamine antagonist, serotonin antagonist, and substance P antagonist administered to patients according to emetogenic risk of chemotherapeutic drugs. However, patients don't always experience same nausea and vomiting for the same drugs. Therefore, it is important to determine the biomarker to predict chemotherapy-induced nausea and vomiting. Some biomarkers studies were done during the chemotherapy. However it is not definite evidence of relations between biomarkers and chemotherapy. We will hope to find any predictive biomarker of CINV.

Full Title of Study: “Evaluation of Predictive Risk Factors of Chemotherapy-induced Nausea and Vomiting(CINV)”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: November 2017

Detailed Description

1. Primary Objective To evaluate the role of some predictive biomarkers for chemotherapy-induced nausea and vomiting 2. Secondary Objective To evaluate the clinical characteristics related to chemotherapy-induced nausea and vomiting in Korean patients 3. Study design Chemotherapy Day Day1 Day3 Day15 Chemotherapy 1st cycle FOLFOX/ FOLFIRI 2nd cycle FOLFOX/ FOLFIRI Blood Sampling 1st sampling (8 a.m.) 2nd sampling (8 a.m.) 3rd sampling (8 a.m.) Evaluation of nausea and vomiting Patient's Diary (Day 1-4) 4. Evaluation of chemotherapy-induced nausea and vomiting – Patient's Diary consisting of the following three elements: 1. NCI-CTCAE (National cancer institute-common toxicity criteria adverse event) version 4.0 2. 100mm Visual Analog Scale (VAS) 3. Functional living index- emesis – Patients should write 'Patient's Diary' from chemotherapy day 1 to chemotherapy day 4. 5. Evaluation of the serum levels of Biomarkers (substance P et. al.) 1) Blood sampling – Sample 1: 1st cycle, chemotherapy starting day 1, fasting 8 a.m. – Sample 2: 1st cycle, chemotherapy day 3, fasting 8 a.m. – Sample 3: 2nd cycle, chemotherapy starting day 1 (day 15 after 1st cycle chemotherapy), fasting 8 a.m. 2) ELISA test for biomarkers (Sample 1,2,3) 5. Visiting Schedule Screening Chemotherapy Time of Visit D-3 to -1 1st day of 1st cycle (Day 1) 3rd day of 1st cycle (Day 3) 4th day of 1st cycle (Day4) 1st day of 2nd cycle (Day 15) Inclusion/exclusion criteria x Informed consent x Distribution of patient's diary x Blood sampling x x x Return of patient's diary x 6. Statistical methods and data analysis Continuous variables, including serum levels of biomarkers, are expressed as median, minimum, and maximum values. Comparisons of continuous variables are made using the Mann-Whitney U test and the Kruskal-Wallis test. The chi-square test is used for comparisons of categorical variables.

Arms, Groups and Cohorts

  • CINV of FOLFOX, FOLFIRI
    • moderate emetogenic chemotherapy

Clinical Trial Outcome Measures

Primary Measures

  • To evaluate the role of some predictive biomarkers for chemotherapy-induced nausea and vomiting
    • Time Frame: 2 weeks after chemotherapy
    • Chemotherapy Day Day1 Day3 Day15 Chemotherapy st cycle FOLFOX/ FOLFIRI nd cycle FOLFOX/ FOLFIRI Blood Sampling 1st sampling (8 a.m.) 2nd sampling (8 a.m.) 3rd sampling (8 a.m.) Evaluation of nausea and vomiting Patient’s Diary (Day 1-4)

Secondary Measures

  • To evaluate the clinical characteristics related to chemotherapy-induced nausea and vomiting in Korean patients
    • Time Frame: 2 weeks after chemotherapy
    • Patient’s Diary consisting of the following three elements: NCI-CTCAE (National cancer institute-common toxicity criteria adverse event) version 4.0 100mm Visual Analog Scale (VAS) Functional living index- emesis Patients should write ‘Patient’s Diary’ from chemotherapy day 1 to chemotherapy day 4. Evaluate about clinical history of patients

Participating in This Clinical Trial

Inclusion Criteria

  • Minimum age of 18 years – Histologically proven solid organ cancer – Eastern Cooperative Oncology Group Performance status 0-2 – More than 3 months for life expectancy – Patients scheduled to receive the first line, first cycle FOLFOX (5-FU, Oxaliplatin, Leucovorin) or FOLFIRI (5-FU, Irinotecan, Leucovorin) chemotherapy – Patients must sign an informed consent indicating that they are aware of the investigational nature of the study in keeping with the policy of the hospital Exclusion Criteria:

  • Patients who have nausea and vomiting caused by other reasons such as CNS metastases or gastrointestinal obstruction – Patients who were exposed previously to any chemotherapy except adjuvant FL (5-FU and leucovorin) – Patients who take anti-emetic drugs or dopamine antagonist within 72 hours prior to administration of chemotherapy – Patients who take other drugs that may affect serum level of biomarkers (ex. steroid, megesterol, hormone replacement therapy, parenteral nutrition)

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • The Catholic University of Korea
  • Provider of Information About this Clinical Study
    • Principal Investigator: Byoungyong Shim, Associate professor – The Catholic University of Korea
  • Overall Official(s)
    • Byoungyong Shim, M.D., Ph.D., Principal Investigator, Department of medical oncology, The Catholic University of Korea

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.